MIRUM PHARMACEUTICALS, INC.

(MIRM)
  Report
Real-time Estimate Cboe BZX  -  05/20 10:13:36 am EDT
25.20 USD   +4.07%
05/18Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
BU
05/10Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
05/05MIRUM PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

01/04/2022 | 08:32am EDT

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will present at the annual J.P. Morgan Healthcare Conference taking place virtually January 10-13, 2022.

Chris Peetz, Mirum’s president and chief executive officer, will provide an overview of Mirum’s strategy and ongoing development program, as well as a commercial update for LIVMARLI™ (maralixibat) oral solution. Mr. Peetz and members of Mirum’s leadership team will be available for one-on-one meetings during the conference.

Presentation and Q&A Session

Date: Tuesday, January 11, 2022
Time: 1:30 – 2:10 p.m. ET

A live audio webcast and archive of Mirum’s presentation along with accompanying slides will be available in the Investors & Media section of the company’s website.

Additionally, the company will participate in a fireside chat at the upcoming H.C. Wainwright Virtual BIOCONNECT 2022 Conference. A webcast of the presentation will be accessible from the Investors & Media section of Mirum’s website beginning January 10, 2022, at 7:00 a.m. ET.

Visit the Investors and Media section of Mirum’s corporate website for additional information.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum’s approved medication is LIVMARLI™ (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older.

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open in Canada, Australia, the UK and several countries in Europe for eligible patients with Alagille syndrome.

Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome.

Mirum’s second investigational treatment, volixibat, also an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the OHANA Phase 2b study for pregnant women with intrahepatic cholestasis of pregnancy, VISTAS Phase 2b study for adults with primary sclerosing cholangitis, and the VANTAGE Phase 2b study for primary biliary cholangitis.

To augment its pipeline in cholestatic liver disease, Mirum has acquired the exclusive option to develop and commercialize gene therapy programs VTX-803 and VTX-802 for PFIC3 and PFIC2, respectively, from Vivet Therapeutics SAS, following preclinical evaluation and investigational new drug-enabling studies.

Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.


© Business Wire 2022
All news about MIRUM PHARMACEUTICALS, INC.
05/18Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
BU
05/10Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
05/05MIRUM PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
05/05TRANSCRIPT : Mirum Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 05, 2022
CI
05/05Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Busines..
BU
05/05Mirum Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March ..
CI
05/05Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Reports Q1 Revenue $12.9M, vs. Street Est o..
MT
05/02Mirum Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Confere..
BU
04/26SVB Leerink Adjusts Mirum Pharmaceuticals' Price Target to $49 from $46, Keeps Outperfo..
MT
04/08Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
More news
Analyst Recommendations on MIRUM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 72,1 M - -
Net income 2022 -154 M - -
Net cash 2022 131 M - -
P/E ratio 2022 -5,45x
Yield 2022 -
Capitalization 769 M 769 M -
EV / Sales 2022 8,85x
EV / Sales 2023 4,07x
Nbr of Employees 144
Free-Float 95,1%
Chart MIRUM PHARMACEUTICALS, INC.
Duration : Period :
Mirum Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIRUM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 24,21 $
Average target price 57,14 $
Spread / Average Target 136%
EPS Revisions
Managers and Directors
Christopher Peetz President, Chief Executive Officer & Director
Ian Clements Chief Financial Officer
Michael G. Grey Chairman
Pamela Vig Head-Research & Development
Peter Radovich Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
MIRUM PHARMACEUTICALS, INC.51.79%769
MODERNA, INC.-43.55%57 031
LONZA GROUP AG-29.91%40 761
IQVIA HOLDINGS INC.-28.50%38 185
SEAGEN INC.-7.74%26 255
ICON PUBLIC LIMITED COMPANY-30.82%17 418